ArticleFrontiers in pediatrics2026
CFTR mutations and genotypic patterns among cystic fibrosis patients with allergic bronchopulmonary aspergillosis: analysis from a tertiary care center in Saudi Arabia.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cystic fibrosis (CF) is a multisystem disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Allergic bronchopulmonary aspergillosis (ABPA) is a recognized complication in CF, with genetic variability potentially influencing susceptibility. This study aims to assess the distribution of CFTR genotype classes in CF patients with ABPA and explore their association with disease severity and baseline pulmonary function. Methods: A retrospective cross-sectional study was conducted over a 10-year period, including patients <18 years with genetically confirmed CF and concomitant ABPA. CFTR mutation data were analyzed, and comparative analyses were performed across CFTR genotype classes. Results: Twenty-two patients were included, with a median age of 13.75 years at the time of ABPA diagnosis. CFTR mutations identified were predominantly classified as Class I (72.7%), followed by Class II (22.7%), with a single patient harboring a Class V mutation. Patients with Class II/V mutations showed lower growth indices and baseline pulmonary function compared to Class I, without statistical significance ( Conclusion: CFTR genotype may influence clinical phenotype in CF patients with ABPA, with trends toward poorer growth and lung function in more severe mutation classes, although larger studies are needed to confirm these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.